Image source: Shutterstock

Highlights

  • FY25 EBITDA now expected to exceed $4.5 million, up from previous guidance of >$3 million

  • Share price jumped 15.4% to 10.5 cents following the announcement

  • Growth supported by contract extensions, product upgrades, and favourable FX impact

Alcidion Group Limited (ASX:ALC) shares climbed 15.4% to 10.5 cents on Monday, 23 June 2025, after the company released a trading update featuring a substantial upgrade to its full-year EBITDA guidance. The market responded positively to the increased financial outlook.

Revised Guidance Points to Improved Financial Outcomes

In its latest update, Alcidion revised its FY25 EBITDA guidance to exceed $4.5 million, significantly higher than its previous estimate of more than $3.0 million. This upward revision is attributed to a combination of multiple contributing factors, including incremental contract extensions, additional product module upgrades from existing clients, prudent cost management, and supportive foreign exchange movements.

CEO and Managing Director Kate Quirke highlighted that the company’s flagship Miya Precision platform has proven to be an entry point for deeper engagement with customers. “Deployments of our Miya platform continue to build referenceability and a positive net return for our customers,” she said. “This is leading hospitals to expand their usage of Alcidion’s solutions to address wider operational needs.”

Customer Engagement Driving Organic Growth

Alcidion noted that several customers — both large and small — had recently requested additional product modules or contract extensions. These organic upsell opportunities have become a consistent source of revenue growth and have contributed materially to the improved financial performance for FY25.

The Miya platform, central to Alcidion’s offering, integrates clinical decision support, communication tools, and operational dashboards. This allows hospitals to manage tasks and patient care in a more centralised, efficient way. 

Long-Term Outlook Backed by Expanding Pipeline

Alcidion is also seeing a rise in inbound interest from both new and existing clients, underscoring what the company describes as confidence in the longer-term utility of its healthcare technology. Kate Quirke added, “We continue to see new opportunities, providing confidence in our ability to address the critical challenges faced by hospital systems globally.”

Investors can expect more detail in the company’s upcoming Q4 quarterly report, scheduled for release on 24 July 2025, followed by its full-year results in August.